



27th July 2010

Omacor® (Omega-3 polyunsaturated fatty acids) in patients with Heart Failure

The New Therapies Subgroup discussed the above drug at a meeting on 27th July 2010. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Omacor® in patients with heart failure.

The group does not recommend the use of Omacor® in patients with heart failure.

Although trial results are promising, further studies are needed prior to recommending routine use. Omacor® remains unlicensed for this indication and it is unclear whether the trial results would be applicable to the UK population.

However as omega-3 polyunsaturated fatty acids are well tolerated, there would appear to be no reason why patients cannot buy supplements if they wish to do so, especially if they are unable to obtain the required amount from their diet (e.g. eating oily fish)

According to set criteria Omacor® was deemed to be low priority for funding.

Review date: May 2018

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.
\$To be read in conjunction with the SPC.